Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: enclomiphene citrate Clear all
Completed Not applicable Interventional

Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

NCT00005104
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperinsulinism
Interventions
clomiphene citrate, metformin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
5
States / cities
Birmingham, Alabama • Shreveport, Louisiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

NCT01923857
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

NCT01044862
View directory record Official record
Conditions
Pregnancy, Unexplained Infertility
Interventions
Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

NCT03646162
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Veru-944, Placebo
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Los Angeles, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

NCT01386606
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal (enclomiphene citrate), Testosterone
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Pregnancy in Polycystic Ovary Syndrome II

NCT00719186
View directory record Official record
Conditions
Pregnancy, Polycystic Ovary Syndrome
Interventions
Clomiphene citrate, Letrozole
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women

NCT00413179
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions
Metformin, Clomiphene citrate, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Sep 30, 2026, 5:42 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate

NCT05096169
View directory record Official record
Conditions
Testosterone Deficiency
Interventions
Clomiphene Citrate 25mg, Clomiphene Citrate 50mg
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 45 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Placebo, topical testosterone, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation

NCT01291056
View directory record Official record
Conditions
Mood
Interventions
Placebo, Clomiphene
Other · Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

NCT01923870
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

NCT01619683
View directory record Official record
Conditions
Effect of Treatment on Bone Mineral Density
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

NCT02169804
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

NCT00706719
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
25 mg Androxal, Testim 1%
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 30, 2026, 5:42 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI

NCT02510534
View directory record Official record
Conditions
Pregnancy
Interventions
Menopur 150 international units, Endometrin 100 mg
Drug
Lead sponsor
Northwest Center for Infertility and Reproductive Endocrinology
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Margate, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Withdrawn Not applicable Interventional

SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis

NCT02520505
View directory record Official record
Conditions
Endometriosis, Infertility
Interventions
Supraovulation clomiphene citrate, Timed intercourse, Intrauterine Insemination
Drug · Behavioral · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

NCT00213148
View directory record Official record
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

NCT01959685
View directory record Official record
Conditions
Pharmacokinetics, Tolerability
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Not applicable Interventional Results available

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773
View directory record Official record
Conditions
Infertility
Interventions
Intrauterine Insemination, Clomiphene, Letrozole
Procedure · Drug
Lead sponsor
Midwest Fertility Specialists
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Treatment of Infertility in Women With Polycystic Ovary Syndrome

NCT00068861
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions
metformin XR, clomiphene citrate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 30, 2026, 5:42 PM EDT
Active, not recruiting Phase 4 Interventional Results available

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

NCT05206448
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Infertility
Interventions
Letrozole, Clomiphene Citrate
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Davenport, Iowa • Iowa City, Iowa • West Des Moines, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 30, 2026, 5:42 PM EDT